Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
NCT03615235 · View on ClinicalTrials.gov ↗
Study Summary
The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes.
Conditions Studied
Study Locations (18)
New York
- Ichan School of Medicine at Mount Sinai — New York
- Columbia University Irving Medical Center — New York
- Weill Cornell Medicine — New York
Maryland
- University of Maryland School of Medicine — Baltimore
- Johns Hopkins University — Baltimore
North Carolina
- Duke University — Durham
- Wake Forest School of Medicine — Winston-Salem
Alabama
- University of Alabama at Birmingham — Birmingham
California
- University of California San Francisco — San Francisco
Florida
- University of Miami / Miami Transplant Institute — Miami
Georgia
- Emory University School of Medicine — Atlanta
Massachusetts
- Joslin Diabetes Center / Harvard University — Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2019-03-21 |
| Est. Completion | 2027-05-30 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03615235
The ClinicalTrials.gov registry entry for NCT03615235 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,061 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Kidney Diseases appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03615235 reports 18 study locations spanning 14 distinct geographic areas — top geographies include New York, Maryland, North Carolina. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03615235 about?
NCT03615235 is a clinical study titled "APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)". The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in A...
What is the current status of trial NCT03615235?
This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2019-03-21. Estimated completion is 2027-05-30.
What conditions does trial NCT03615235 study?
This clinical trial studies the following conditions: Kidney Diseases, Kidney Failure, Kidney Disease, Chronic. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT03615235?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,061 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03615235 being conducted?
This trial has 18 study locations across Alabama, California, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.